JKN2502

JKN2502 is an investigational, novel antibacterial agent developed by Joincare Pharmaceutical Group and its subsidiary Joincare Haibin Pharmaceutical. It is designed to treat severe infections caused by multi-drug resistant (MDR) Gram-negative bacteria, specifically targeting pathogens such as *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Klebsiella pneumoniae*. The drug is currently undergoing Phase 1 clinical trials in China (e.g., CTR20261589) to evaluate its safety, tolerability, and pharmacokinetics in healthy subjects and individuals with varying degrees of renal impairment. JKN2502 likely functions as a beta-lactam antibiotic, potentially utilizing a siderophore-mediated entry mechanism to overcome common resistance pathways such as porin mutations and efflux pumps, thereby inhibiting penicillin-binding proteins (PBPs) and disrupting bacterial cell wall synthesis.